Impact of Nutritional and Inflammation Status on Long-Term Bleeding in Patients Undergoing Percutaneous Coronary Intervention with an Oral Anticoagulant

Ruka Yoshida1,2, Hideki Ishii3, Itsuro Morishima2, Akihito Tanaka1, Yasuhiro Morita2, Kensuke Takagi2, Naoki Yoshioka2, Kenshi Hirayama3, Naoki Iwakawa3, Hiroshi Tashiro1, Hiroki Kojima1, Takayuki Mitsuda1, Yusuke Hitora3, Kenji Furusawa1, Hideyuki Tsuboi2 and Toyoaki Murohara3

1 Department of Cardiology, Nagoya University Hospital, Nagoya, Japan
2 Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan
3 Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Aim: Patients undergoing percutaneous coronary intervention (PCI) who require both oral anticoagulant (OAC) and antiplatelet therapy (APT) are exposed to a serious risk of bleeding. The aim of this study was to clarify the relationship among nutritional and inflammation status and long-term bleeding in patients requiring both OACs and APT after PCI.

Methods: We performed PCI in 3,718 consecutive patients between April 2011 and March 2017, 302 of whom were treated with both OACs and APT. Patients were followed for up to 3 years for bleeding events, defined as the Bleeding Academic Research Consortium (BARC) class ≥3 bleeding. We retrospectively evaluated the ability of the Geriatric Nutritional Risk Index (GNRI) and high-sensitivity C-reactive protein (hs-CRP) to detect bleeding events.

Results: During a median follow-up of 1,080 days, bleeding events were observed in 53 (17.5%) patients. Bleeding events were associated with a low GNRI (≤98) (hazard ratio [HR], 3.16; 95% confidence interval [CI], 1.84–5.45; p<0.0001) and hs-CRP level ≥2.5 mg/L (HR, 2.75; 95% CI, 1.61–4.78; p=0.0003). A low GNRI + high hs-CRP showed a 5.12-fold increase in the incidence of BARC class ≥3 bleeding (95% CI, 2.68–9.91; p<0.0001) compared with a normal GNRI + low hs-CRP. The addition of the GNRI and hs-CRP to the PRECISE-DAPT score improved C-statistics from 0.67 to 0.71 and enhanced the net reclassification improvement (NRI) and integrated discrimination improvement (IDI) (NRI, 0.36, p<0.0001; IDI, 0.066, p<0.0001).

Conclusions: The GNRI and hs-CRP were novel predictors of the long-term bleeding risk in patients requiring both OACs and APT after PCI.

Key words: Antiplatelet therapy, Oral anticoagulant, Percutaneous coronary intervention, Bleeding events, Geriatric nutritional risk index
Several studies have indicated a relationship between hypoalbuminemia and bleeding events in various conditions\(^9\)\(^-\)\(^11\). Recently, comprehensive nutritional assessment scores, such as the Geriatric Nutritional Risk Index (GNRI)\(^12\) or controlling nutritional status (CONUT) score\(^13\), have emerged, and these scores and inflammation markers were reported to be associated with long-term adverse events\(^14\)\(^-\)\(^16\). However, little is known about the relationship between nutritional status, inflammation, and long-term bleeding events in patients who are taking both OACs and antiplatelet agents after PCI.

### Aim

The aim of this study was to investigate the relationship between the GNRI, C-reactive protein (CRP), and long-term bleeding events in patients undergoing PCI who required both OACs and APT.

### Methods

#### Patient Population

The study population was first collected at single Japanese tertiary hospital to evaluate the predictive performance of various bleeding risk scores, and has been described previously\(^8\). In brief, among 3,718 patients who underwent PCI from April 2011 to March 2017, patients with indications for long-term OAC treatment were enrolled. Exclusion criteria were as follows: history of intracranial bleeding, cardiogenic shock, patients who did not take antiplatelet agents, peptic ulcer in the previous 6 months, thrombocytopenia (platelet count, \(< 50 \times 10^9$/L\)), major bleeding (according to the Thrombolysis in Myocardial Infarction criteria\(^17\)) in the previous 12 months, and a life expectancy of less than 12 months. The indication for PCI was based on established European\(^18\), American\(^19\), and Japanese\(^20\) guidelines. This study was approved by the research review board of our hospital. Moreover, this study was conducted according to the tenets of the Helsinki Declaration. All patients provided consent for participation in this study.

#### Antithrombotic Treatment

The details of the antithrombotic treatment also have been described previously\(^8\). All patients received at least one antiplatelet agent (thienopyridine [200 mg ticlopidine, 75 mg clopidogrel, or 3.75 mg prasugrel daily] and/or 81–100 mg aspirin daily) and an OAC (vitamin K antagonist or a direct OAC [DOAC]). The type and timing of discontinuing antiplatelet agents, and the selection of the OAC were at the discretion of each attending physician. In the periprocedural period, OACs were continued if possible.

#### GNRI and High-Sensitivity CRP

The patient's serum albumin level, body weight (BW), and height were measured before PCI. The GNRI was calculated by modifying the GNRI as follows\(^21\):

\[
\text{GNRI} = (14.89 \times \text{albumin [g/dL]} + 41.7 \times \frac{\text{BW}}{\text{ideal BW}}),
\]

where the BW/iBW was set to 1 when the patient's BW exceeded the iBW. The iBW in the present study was calculated from a body mass index (BMI) of 22, which is associated with the lowest mortality\(^22\). Then, patients were divided into two groups based on previous studies as follows: GNRI \(\leq 98\) (low GNRI) and \(> 98\) (normal GNRI)\(^12\).

Serum high-sensitivity CRP (hs-CRP) levels were determined using a latex immune-nephelometry method (NITTOBO MEDICAL, Tokyo, Japan). Receiver operating characteristic curve analyses were carried out to examine the optimal cutoff value of hs-CRP to predict bleeding events. Subsequently, patients were divided into two groups based on the best cutoff value: low hs-CRP and high hs-CRP.

To estimate the combined effects of the GNRI with hs-CRP on predicting bleeding events, patients were divided into four groups: normal GNRI \& low hs-CRP; normal GNRI \& high hs-CRP; low GNRI \& low hs-CRP; and low GNRI \& high hs-CRP.

#### Assessments and Follow-Up

Demographic, angiographic, and procedural data were collected from hospital charts or hospital databases. Follow-up data were obtained from hospital charts or by contacting patients telephonically for up to 3 years. All patient follow-up data were obtained by March 2018.

The primary outcome of this study was out-of-hospital bleeding defined as the Bleeding Academic Research Consortium (BARC)\(^23\) class \(\geq 3\) and occurring 7 days or later after the index PCI; bleeding that occurred earlier was censored. We selected 7 days as a conservative time frame based on the current trend in the length of hospital stay for patients with acute coronary syndrome and to exclude events related to the index PCI procedure.

Anemia was classified as a hemoglobin level \(< 12\) g/dL in men and \(< 11\) g/dL in women\(^24\). The estimated glomerular filtration rate (eGFR) was calculated using the following equation for Japanese patients recommended by the Japanese Society of Nephrology:
All statistical analyses were performed using JMP software version 13.1 (SAS Institute Inc., Cary, NC, USA) and R version 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria). A p-value < 0.05 was considered statistically significant.

Results

Statistical Analyses

Continuous variables were summarized as the mean and standard deviation (SD) or the median and interquartile range (IQR), and categorical variables are shown as numbers and proportions. Continuous variables were compared using Student’s *t*-test or the Wilcoxon rank-sum test based on their distributions. Categorical variables were compared using chi-squared tests.

Bleeding event rates at 3 years were calculated using the Kaplan–Meier method and compared using the log-rank test. Since the PRECISE-DAPT score was best able to stratify bleeding events of patients who required both OACs and APT after PCI among four famous bleeding risk scores (HAS-BLED, ORBIT, PRECISE-DAPT, and PARIS scores), we adopted it as the reference bleeding score. Thus, a Cox proportional hazards model was used to estimate the contribution of the PRECISE-DAPT score, GNRI, and continuous values of hs-CRP levels to predict bleeding events.

Model discrimination was assessed using the C-statistic. Improvements in predictive accuracy were determined by calculating the net reclassification improvement and the integrated discrimination improvement.

Patient Characteristics

Of the 3,718 patients who underwent PCI during the study period, we identified 302 eligible patients who took both OACs and antiplatelet agents. Of these 302 patients, 87 had a low GNRI and 215 had a normal GNRI (Fig. 1). The clinical characteristics of the recruited patients are summarized in Table 1. The overall follow-up rate was 92.1%. The median length of follow-up was 787 (IQR=424–1,080) days for the low GNRI group and 1,080 (IQR=671–1,080) days for the normal GNRI group. Advanced age, female sex, and a high prevalence of heart failure were significantly more frequent in the low GNRI group. A low GNRI was also associated with decreased total cholesterol, low-density lipoprotein cholesterol, triglyceride levels, and eGFR, and increased glycated hemoglobin, hs-CRP, and brain natriuretic peptide levels.

The mean PRECISE-DAPT score was significantly higher in the low GNRI group than in the normal GNRI group (PRECISE-DAPT: low GNRI, 35.6 [SD=...
Table 1. Patient’s clinical characteristics, medication, and procedural characteristics at baseline

| Clinical baseline characteristics | low GNRI (n=87) | normal GNRI (n=215) | p value |
|---------------------------------|-----------------|---------------------|--------|
| Mean (SD) age (years)           | 76.9 (9.0)      | 70.2 (8.6)          | <0.0001|
| Male sex                        | 57 (65.5%)      | 178 (82.8%)         | 0.001  |
| Mean (SD) BMI (kg/m²)           | 21.0 (3.5)      | 24.4 (3.5)          | <0.0001|
| Diabetes mellitus               | 47 (54.0%)      | 90 (41.9%)          | 0.05   |
| Hypertension                    | 62 (71.3%)      | 162 (75.4%)         | 0.47   |
| Dislipidemia                    | 42 (48.3%)      | 148 (68.8%)         | 0.001  |
| Smoking history                 | 57 (65.5%)      | 134 (62.3%)         | 0.60   |
| Prior myocardial infarction     | 18 (20.7%)      | 60 (27.9%)          | 0.19   |
| Prior heart failure             | 65 (74.7%)      | 76 (35.4%)          | <0.0001|
| Prior stroke                    | 15 (17.2%)      | 27 (12.6%)          | 0.30   |
| Prior PCI                       | 31 (35.6%)      | 85 (39.5%)          | 0.53   |
| Prior CABG                      | 16 (18.4%)      | 42 (19.5%)          | 0.82   |
| Serum albumin (g/dl)            | 3.6 (0.3)       | 4.3 (0.3)           | <0.0001|
| Total cholesterol (mg/dl)       | 152.8 (34.4)    | 172.4 (41.0)        | 0.0001 |
| LDL-cholesterol (mg/dl)         | 89.5 (29.2)     | 104.1 (35.0)        | 0.001  |
| HDL-cholesterol (mg/dl)         | 40.3 (12.8)     | 42.7 (10.6)         | 0.09   |
| Triglyceride (mg/dl)            | 90 [60, 128]    | 117 [74, 171]       | 0.003  |
| Glycated hemoglobin (%)         | 6.0 (1.3)       | 5.7 (0.9)           | 0.03   |
| hs-CRP (mg/dl)                  | 0.27 [0.13, 0.51]| 0.1 [0.05, 0.24]    | <0.0001|
| BNP (pg/ml)                     | 291.6 [155.1, 606.2] | 81.6 [39.7, 180.2] | <0.0001|
| eGFR (ml/min/1.73 m²)           | 53.3 (24.7)     | 65.2 (19.8)         | <0.0001|
| PRECISE-DAPT score              | 35.6 (16.3)     | 24.9 (11.3)         | <0.0001|
| Medication at discharge         |                 |                     |        |
| Aspirin                         | 74 (85.1%)      | 195 (90.7%)         | 0.17   |
| Thienopyridine                  | 84 (96.6%)      | 197 (91.6%)         | 0.10   |
| DAPT                            | 73 (83.9%)      | 177 (82.3%)         | 0.74   |
| PPI                             | 83 (95.4%)      | 197 (91.6%)         | 0.23   |
| Type of OAC                     |                 |                     | 0.27   |
| VKA                             | 55 (63.2%)      | 121 (56.3%)         |        |
| DOAC                            | 32 (36.7%)      | 94 (43.7%)          |        |
| Indication for OAC              |                 |                     | 0.87   |
| Atrial fibrillation             | 58 (66.7%)      | 150 (69.7%)         |        |
| Post cardiac surgery            | 15 (17.2%)      | 54 (15.8%)          |        |
| Other (apical aneurysm, pulmonary embolism, PAD) | 14 (16.1%) | 31 (14.4%) |        |
| DAPT continuation (continue number/survivor, %) | | | |
| At 1 month                      | 77/87 (88.5%)   | 180/214 (84.1%)     | 0.42   |
| At 3 months                     | 55/85 (64.7%)   | 139/212 (65.6%)     | 0.89   |
| At 6 months                     | 46/84 (54.8%)   | 106/211 (50.2%)     | 0.52   |
| At 12 months                    | 24/76 (31.6%)   | 75/207 (36.2%)      | 0.49   |
| Procedural characteristics      |                 |                     |        |
| DES                             | 66 (75.9%)      | 141 (65.6%)         | 0.08   |
| Indication of PCI              |                 |                     | 0.34   |
| STEMI                           | 27 (31.0%)      | 66 (30.7%)          |        |
| NSTEMI                          | 3 (3.5%)        | 4 (1.9%)            |        |
| Unstable AP                     | 13 (14.9%)      | 19 (8.8%)           |        |
| Stable AP                       | 44 (50.6%)      | 126 (58.6%)         |        |

Values are the mean ± standard deviation (SD), n (%), or median (interquartile range) as appropriate. GNRI, geriatric nutritional risk index; BMI, body-mass index; PCI, percutaneous coronary intervention; CAGB, coronary artery bypass graft; LDL, low-density lipoprotein; HDL, high-density lipoprotein; hs-CR, high-sensitivity C-reactive protein; BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate; DAPT, dual antiplatelet therapy; PPI, proton-pump inhibitor; OAC, oral anticoagulant; VKA, vitamin K antagonist; DOAC, direct oral anticoagulant; PAD, peripheral artery disease; DES, drug eluting stent; STEMI, ST elevation myocardial infarction; NSTEMI, non-ST elevation myocardial infarction; AP, angina pectoris.
hazard ratio [HR], 3.16; 95% confidence interval [CI], 1.84–5.45; \( p < 0.0001 \) (Fig. 2A).

hs-CRP levels were divided using an optimal cut-off value of 2.5 mg/L (area under the curve \( AUC = 0.64; p < 0.0001 \)). Results for the low hs-CRP (<2.5 mg/L) and high hs-CRP (≥2.5 mg/L) groups were BARC class ≥3 bleeding in 35.7% and 13.2% of patients, respectively (HR, 2.75; 95% CI, 1.61–4.78; \( p = 0.0003 \)) (Fig. 2B). Regarding the combined effects of GNRI and hs-CRP, low GNRI + high hs-CRP showed a 5.12-fold increase in the incidence of BARC class ≥3 bleeding (95% CI, 2.68–9.91; \( p < 0.0001 \)) compared with normal GNRI + low hs-CRP. In contrast, no significant increase was observed in the incidence of bleeding events for normal GNRI + high hs-CRP or low GNRI + low hs-CRP compared with normal GNRI + low hs-CRP (Fig. 2C).
GNRI and CRP as Markers for Bleeding

Cox proportional hazards modeling is shown in Table 2. After adjustment for the PRECISE-DAPT score, a low GNRI independently predicted adverse bleeding events (HR, 2.13; 95% CI, 1.17–3.87; \( p = 0.01 \)); after adjustment for both the PRECISE-DAPT score and hs-CRP, a low GNRI tended to be associated with the increased incidence of bleeding events. (HR, 1.75; 95% CI, 0.96–3.20; \( p = 0.07 \)). In contrast, hs-CRP independently predicted bleeding events after adjustment for the PRECISE-DAPT score and GNRI.

The C-statistic for BARC class ≥3 bleeding was 0.67 (95% CI, 0.52–0.64; \( p = 0.001 \)) for the PRECISE-DAPT score alone. Adding the GNRI and hs-CRP to the PRECISE-DAPT score increased the predictive accuracy of bleeding events (Table 3).

### Discussion

In this study, we assessed the comprehensive nutritional assessment score and inflammation marker as risk factors for long-term bleeding events in patients treated with PCI who required both OACs and APT. The main findings of the present study were as follows:

1. The GNRI was able to discriminate bleeding risk in patients who underwent PCI and required both OACs and APT.
2. hs-CRP was an independent predictor of long-term bleeding events by Cox proportional hazards analysis.
3. The combination of the GNRI and hs-CRP could detect the patients with the highest risk of bleeding events.
4. The addition of the GNRI and hs-CRP to the PRECISE-DAPT score, which is an established bleeding risk score, significantly improved the ability to stratify bleeding risk in these patients.

Our study highlighted the clinical impact of nutritional status and inflammation on long-term bleeding events in those who required both OACs and APT after PCI. Bleeding complications are associated with an increased risk of subsequent adverse outcomes, such as death, myocardial infarction, stroke, and stent thrombosis. Therefore, it is very important to identify high risk patients; however, it is difficult to predict bleeding events, particularly in patients who require both OACs and APT. In the present study, the GNRI and hs-CRP could discriminate the bleeding risk in this subset of patients. Moreover, adding the GNRI and hs-CRP increased the accuracy to discriminate bleeding events of the established bleeding risk score (PRECISE-DAPT score). In this regard, the result of the present study offered information of importance.

In previous studies, the GNRI has been recognized as a nutrition-related risk index that makes it possible to stratify the risk of morbidity and mortality in relation to pathologies in elderly patients, which are often associated with malnutrition. The GNRI appraises the BMI as well as serum albumin levels. In the present study, the addition of BMI alone to the PRECISE-DAPT score did not improve its ability to predict bleeding events compared with the GNRI. There could be various reasons for this. Previous epidemiologic studies have found that underweight patients were associated with a greater incidence of bleeding complications than normal-weight patients. However, the relationship between BMI and bleeding events was a reverse J-shape or a U-shape, which demonstrated the lowest risk in patients with a normal BMI compared with underweight or overweight patients. Moreover, BMI alone may not distinguish sarcopenic obesity, an expression of the loss of lean body mass and increased fat mass, which has been recognized as a risk for multimorbidity in some populations. Therefore, it might be important to assess BMI together with nutritional status, and the GNRI was appropriate for this purpose.

There are several other nutritional screening tools, and each has its advantages and disadvantages. Some are based on subjective data, such as the Subjective Global Assessment and Mini-Nutritional Assessment. Other tools are based on objective biochemical and clinical data, such as the GNRI and the CONUT score. To assess nutritional status correctly,
combining both subjective and objective tools is important. However, for daily clinical practice, an objective and simple tool that uses routinely measured data is desirable. Furthermore, subjective indices require the training and experience of medical practitioners, and it might be affected by the questioner’s opinions. The GNRI, which uses only serum albumin level and BMI, is an easy and efficient screening tool to assess the nutritional status of patients undergoing PCI.

It has been suggested that a large proportion of patients at high risk for atherosclerosis also had a high bleeding risk, reflecting an overlap of the risk predictors for thrombosis and bleeding. A sub-analysis of the DAPT study revealed that polyvascular disease was a strong predictor of bleeding events as well as a predictor of ischemic events. Inflammation is also known to play an important role in the initiation and progression of atherosclerosis. In the present study, hs-CRP, which is a popular marker of inflammation, was revealed to be useful for predicting bleeding events after PCI. It is very difficult to show the mechanism underlying the effect of inflammation on the bleeding risks from the results of this observational study. However, several studies have demonstrated that systemic inflammation is correlated with advanced age and sarcopenia. In the present study, patients with a low GNRI were significantly older and had higher hs-CRP levels than patients with a normal GNRI. When considered comprehensively, bleeding events might be involved in the context of a malnutrition–inflammation–atherosclerosis syndrome, which is a malignant cycle propounded in patients with chronic kidney disease, formed by malnutrition and inflammation. Therefore, it was suggested that assessing both nutritional and inflammation status as well as established risk factors was required to improve the identification of patients at high risk for bleeding among those who underwent PCI and required both OACs and APT.

The role of bleeding risk scores should be to identify high risk patients for a more careful review and follow-up, as well as to draw attention to reversible factors. From this perspective, the GNRI is simple, practical, and reversible; until now, data on interventions in nutritional status that improve the risk for long-term bleeding events have been limited. Thus, future studies should investigate if nutritional intervention will improve the risk for bleeding events in patients taking both OACs and antiplatelet agents after PCI.


table 3. Discrimination of each predictive model of Adverse Bleeding Events (BARC class ≥ 3 bleeding)

| Variables                | C-statistic | p value | NRI     | p value | IDI     | p value |
|--------------------------|-------------|---------|---------|---------|---------|---------|
| PRECISE-DAPT             | 0.67        | <0.0001 | Reference|         |         | Reference|
| + BMI                    | 0.68        | <0.0001 | 0.01    | 0.51    | 0.001   | 0.45    |
| + Alb                    | 0.67        | <0.0001 | 0.06    | 0.44    | 0.005   | 0.26    |
| + low GNRI               | 0.69        | <0.0001 | 0.30    | 0.02    | 0.028   | 0.04    |
| + hs-CRP                 | 0.70        | <0.0001 | 0.28    | 0.01    | 0.051   | <0.0001 |
| + low GNRI and hs-CRP    | 0.71        | <0.0001 | 0.36    | 0.02    | 0.066   | <0.0001 |

PRECISE-DAPT, PRECISE-DAPT score; GNRI, geriatric nutritional risk index; hs-CRP, high-sensitivity C-reactive protein; NRI, net reclassification improvement; IDI, integrated discrimination improvement.
Conclusion

The GNRI and hs-CRP are novel predictors of long-term bleeding risk in patients taking both OACs and antiplatelet agents after PCI. Adding the GNRI and hs-CRP to the PRECISE-DAPT score improved the ability to stratify bleeding risk in these patients.

Conflict of Interest

H.I. received lecture fees from Astellas Pharma Inc., Bayer Pharmaceutical Co., Ltd., and MSD K. K. T.M. received lecture fees from Bayer Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Kowa Co., Ltd., MSD K. K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K. K., Pfizer Japan Inc., Sanofi-aventis K. K., and Takeda Pharmaceutical Co., Ltd. T.M. received an unrestricted research grant for the Department of Cardiology, Nagoya University Graduate School of Medicine from Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Kowa Co., Ltd., MSD K. K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K. K., Otsuka Pharma Ltd., Pfizer Japan Inc., Sanofi-aventis K. K., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. The other authors have nothing to disclose.

Research Funding

This study was supported by a grant from Aichi Kidney Foundation and Grant-in-Aid for Scientific Research (KAKENHI) (No. 17 K 0 9 4 9 3) of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) and the Japanese Society for the Promotion of Science (JSPA).

References

1) Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, Kirchhof P, Marin F and European Society of Cardiology Working Group on T: Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost. 2010; 103: 13-28
2) Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerring Olsen AM, Mikkelsen A, Christensen CB, Lip GY, Kober L, Torp-Pedersen C and Hansen ML: Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013; 62: 981-989
3) Yoshida R, Morishima I, Takagi K, Morita Y, Tsuboi H and Murohara T: Comparison Between Long-Term Clinical Outcomes of Vitamin K Antagonist and Direct Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Circ J. 2018; 82: 2016-2024
4) Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, Ariti C, Litherland C, Dangas G, Gibson CM, Krucoff MW, Moliterno DJ, Kirtane AJ, Stone GW, Colombo A, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG and Pocock S: Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. J Am Coll Cardiol. 2016; 67: 2224-2234
5) Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijs HJ and Lip GY: A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138: 1093-1100
6) Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M and Investigators P-DS: Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient data-sets from clinical trials. Lancet. 2017; 389: 1025-1034
7) Kiviniemi T, Puurunen M, Schlitt A, Rubboli A, Karjalainen P, Vikman S, Niemela M, Lahtela H, Lip GY and Airaksinen KE: Performance of bleeding risk-prediction scores in patients with atrial fibrillation undergoing percutaneous coronary intervention. Am J Cardiol. 2014; 113: 1995-2001
8) Yoshida R, Ishii H, Morishima I, Tanaka A, Morita Y, Takagi K, Yoshioka N, Hirayama K, Iwakawa N, Tashiro H, Kojima H, Mitsuda T, Hitara Y, Furusawa K, Tsuboi H and Murohara T: Performance of HAS-BLED, ORBIT, PRECISE-DAPT, and PARIS risk score for predicting long-term bleeding events in patients taking an oral anti-coagulant undergoing percutaneous coronary intervention. J Cardiol. 2018 in press
9) Tatami Y, Ishii H, Aoki T, Harada K, Hirayama K, Shibata Y, Sumi T, Negishi Y, Kawashima K, Kunimura A, Kawamiya T, Yamamoto D, Suzuki S and Murohara T: Decreased Serum Albumin Predicts Bleeding Events in Patients on Antiplatelet Therapy After Percutaneous Coronary Intervention. Circ J. 2017; 81: 999-1005
10) Engelman DT, Adams DH, Byrne JG, Aranki SF, Collins JJ, Jr., Couper GS, Allred EN, Cohn LH and Rizzo R: Impact of body mass index and albumin on morbidity and mortality after cardiac surgery. J Thorac Cardiovasc Surg. 1999; 118: 866-873
11) Kinugasa Y, Kato M, Sugihara S, Hirai M, Yamada K, Yanagihara K and Yamamoto K: Geriatric nutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fraction. Circ J. 2013; 77: 705-711
12) Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I, Benazeth S, Cynober L and Ausset C: Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr. 2005; 82: 777-783
13) Ignacio de Ulibarri J, Gonzalez-Madrono A, de Villar NG, Gonzalez P, Gonzalez B, Mancha A, Rodriguez F and Fernandez G: CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp. 2005; 20: 38-45
14) Kunimura A, Ishii H, Uetani T, Aoki T, Harada K, Hirayama K, Negishi Y, Shibata Y, Sumi T, Kawashima K, Tatsuki T, Kawamiya T, Yamamoto D, Suzuki S, Amano T and Murohara T: Impact of nutritional assessment and body mass index on cardiovascular outcomes in patients with stable coronary artery disease. Int J Cardiol. 2017; 230: 653-658
15) Kunimura A, Ishii H, Uetani T, Aoki T, Harada K, Hirayama K, Negishi Y, Shibata Y, Sumi T, Kawashima K, Tatsuki T, Kawamiya T, Yamamoto D, Suzuki S, Amano T and Murohara T: Impact of Geriatric Nutritional Risk Index on cardiovascular outcomes in patients with stable coronary artery disease. J Cardiol. 2017; 69: 383-388
16) Kawamiya T, Suzuki S, Ishii H, Hirayama K, Harada K, Shibata Y, Tatsuki T, Harata S, Kawashima K, Kunimura A, Takayama Y, Shimbo Y, Osugi N, Yamamoto D, Ota T, Kono C and Murohara T: Correlations between geriatric nutritional risk index and peripheral artery disease in elderly coronary artery disease patients. Geriatr Gerontol Intern. 2017; 1075-1062
17) Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P and et al.: Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987; 76: 142-154
18) Windecker S, Kolh P, Alfons F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W and Witkowski A: 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), Eur Heart J. 2014; 35: 2541-2619
19) Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK and Ting HH: 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011; 58: e44-122
20) Guidelines for elective percutaneous coronary intervention in patients with stable coronary artery disease (JCS 2011) published in 2012—digest version. Circ J. 2013; 77: 1590-1607
21) Yamada K, Furuya R, Takita T, Maruyama Y, Yamaguchi Y, Ohkawa S and Kumagai H: Simplified nutritional screening tools for patients on maintenance hemodialysis. Am J Clin Nutr. 2008; 87: 106-113
22) Shah B, Sucher K and Hollenbeck CB: Comparison of ideal body weight equations and published height-weight tables with body mass index tables for healthy adults in the United States. Nutr Clin Pract. 2006; 21: 312-319
23) Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG and White H: Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011; 123: 2736-2747
24) Astor BC, Muntner P, Levin A, Eustace JA and Coresh J: Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2002; 162: 1401-1408
25) Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A and Collaborators developing the Japanese equation for estimated GFR: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53: 982-992
26) Uno H, Tian L, Cai T, Kohane IS and Wei LJ: A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data. Stat Med. 2013; 32: 2430-2442
27) Genereux P, Giustino G, Witzenbichler B, Weisg, Stuckey TD, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffly PF, Mazzaferr E, Yadav M, Frances DP, Palmerini T, Kirtane AJ, Linderland C, Mehran R and Stone GW: Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2015; 66: 1036-1045
28) Montano-Loza AJ, Angulo P, Meza-Junco J, Prado CM, Sawyer MB, Beaumont C, Esfandiari N, Ma M and Barac VE: Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle. 2016; 7: 126-135
29) da Silva Fink J, Daniel de Mello P and Daniel de Mello E: Subjective global assessment of nutritional status - A systematic review of the literature. Clin Nutr. 2015; 34: 785-792
30) Guigoz Y: The Mini Nutritional Assessment (MNA) review of the literature—What does it tell us? The journal of nutrition, health & aging, 2006; 10: 466-485; discussion 485-467
31) Poulia KA, Yannakoulia M, Karageorgou D, Gamaletou M, Panagiotakos DB, Sipsas NV and Zampelas A: Evaluation of the efficacy of six nutritional screening tools to predict malnutrition in the elderly. Clin Nutr. 2012; 31: 378-385
32) Natsuko M, Morimoto T, Yamaji K, Watanabe H, Yoshiki Y, Shiomi H, Nakagawa Y, Furukawa Y, Kadota K, Ando K, Akasaka T, Hanaoka KI, Kozuma K, Tanabe K, Morino Y, Muramatsu T and Kimura T: Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores. J Am Heart Assoc. 2018; 7. doi: 10.1161/JAHA.118.008708
33) Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Steg PG, Massaro JM, Apruzzese PK, Mauri L and Dual Anti-
platelet Therapy Study I: Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. JACC Cardiovasc Interv. 2017; 10: 942-954

34) Shankar A, Li J, Nieto FJ, Klein BE and Klein R: Association between C-reactive protein level and peripheral arterial disease among US adults without cardiovascular disease, diabetes, or hypertension. Am Heart J. 2007; 154: 495-501

35) Ershler WB and Keller ET: Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu

36) Hwang JH, Ryu J, An JN, Kim CT, Kim H, Yang J, Ha J, Chae DW, Ahn C, Jung IM, Oh YK, Lim CS, Han DJ, Park SK, Kim YS, Kim YH and Lee JP: Pretransplant malnutrition, inflammation, and atherosclerosis affect cardiovascular outcomes after kidney transplantation. BMC Nephrol. 2015; 16: 109

37) Roldan V and Marin F: Predicting bleeding risk after coronary surgery: Let’s focus on modifiable risk factors and simple, practical decision making. Thromb Haemat. 2017; 117: 647-649